In September 2022, the US Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib; Bristol-Myers Squibb Company), a tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to ...

Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

January 20, 2012 — The entire National Psoriasis Foundation Medical Board reviewed and updated the Canadian Guidelines for the Management of Plaque Psoriasis to include new treatments such as ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

Medically reviewed by Leah Ansell, MDMedically reviewed by Leah Ansell, MD Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

MARIETTA, Ga. - Greg Morrison of Marietta has been living with plaque psoriasis for more than 30 years. "The rash, it itches constantly," Morrison says. "It flakes. It kind of pinches you, and then ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis—often mistaken for dry skin or ...

If you have plaque psoriasis, the most common form of psoriasis, you know the thick, raised, patches of skin called plaques can be itchy and painful. With mild to moderate cases of plaque psoriasis, ...